Abstract
Tyrosine phosphorylation has a key role in intracellular signaling. Inappropriate proliferation and survival cues in tumor cells often occur as a consequence of unregulated tyrosine kinase activity. Much of the current development of anti-cancer therapies tries to target causative proteins in a specific manner to minimize side-effects. One attractive group of target proteins is the kinases. c-Kit is a receptor tyrosine kinase that normally controls the function of primitive hematopoietic cells, melanocytes and germ cells. It has become clear that uncontrolled activity of c-Kit contributes to formation of an array of human tumors. The unregulated activity of c-Kit may be due to overexpression, autocrine loops or mutational activation. This makes c-Kit an excellent target for cancer therapies in these tumors. In this review we will highlight the current knowledge on the signal transduction molecules and pathways activated by c-Kit under normal conditions and in cancer cells, and the role of aberrant c-Kit signaling in cancer progression. Recent advances in the development of specific inhibitors interfering with these signal transduction pathways will be discussed.
Keywords: Stem cell factor, c-Kit, receptor tyrosine kinase, signal transduction, transformation, cancer, leukemia
Current Cancer Drug Targets
Title: The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Volume: 6 Issue: 1
Author(s): J. Lennartsson and L. Ronnstrand
Affiliation:
Keywords: Stem cell factor, c-Kit, receptor tyrosine kinase, signal transduction, transformation, cancer, leukemia
Abstract: Tyrosine phosphorylation has a key role in intracellular signaling. Inappropriate proliferation and survival cues in tumor cells often occur as a consequence of unregulated tyrosine kinase activity. Much of the current development of anti-cancer therapies tries to target causative proteins in a specific manner to minimize side-effects. One attractive group of target proteins is the kinases. c-Kit is a receptor tyrosine kinase that normally controls the function of primitive hematopoietic cells, melanocytes and germ cells. It has become clear that uncontrolled activity of c-Kit contributes to formation of an array of human tumors. The unregulated activity of c-Kit may be due to overexpression, autocrine loops or mutational activation. This makes c-Kit an excellent target for cancer therapies in these tumors. In this review we will highlight the current knowledge on the signal transduction molecules and pathways activated by c-Kit under normal conditions and in cancer cells, and the role of aberrant c-Kit signaling in cancer progression. Recent advances in the development of specific inhibitors interfering with these signal transduction pathways will be discussed.
Export Options
About this article
Cite this article as:
Lennartsson J. and Ronnstrand L., The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer, Current Cancer Drug Targets 2006; 6 (1) . https://dx.doi.org/10.2174/156800906775471725
DOI https://dx.doi.org/10.2174/156800906775471725 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Novel Rational Drug Design Strategies with Potential to Revolutionize Malaria Chemotherapy
Current Medicinal Chemistry Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry The Wnt Pathway: Emerging Anticancer Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Contractile Properties of Airway Smooth Muscle: How their Defects can be Linked to Asthmatic Airway Hyperresponsiveness?
Current Respiratory Medicine Reviews Higher Levels of Dynamin-related Protein 1 are Associated with Reduced Radiation Sensitivity of Glioblastoma Cells
Current Neurovascular Research Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics
Current Pharmaceutical Design MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Current Proteomics Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Role of Growth Factors in the Pathogenesis of Tissue Fibrosis in Systemic Sclerosis
Current Rheumatology Reviews Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design Tackling COVID-19 Through Ayurveda: A Review on the Herbs of Recommended Indian Remedies
Current Traditional Medicine AAV Hybrid Serotypes: Improved Vectors for Gene Delivery
Current Gene Therapy Allosteric Inhibitors of Bcr-Abl: Towards Novel Myristate-Pocket Binders
Current Pharmaceutical Biotechnology New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Current Pharmaceutical Design Therapeutic Antibodies
Current Molecular Medicine